The Sentynl option agreement is the primary catalyst—exercise would provide $40M in near-term cash and fund the Phase 3 alvelestat trial. Watch for Sentynl's decision on option exercise and any regulatory update on setrusumab by year-end 2026. The improved cash runway into late-2027 reduces near-term dilution risk.
Price Chart
Executive Summary
Mereo BioPharma reported Q2 2026 results with a net loss of $7.0M, improved from a $14.6M loss in Q2 2025, driven by reduced R&D and G&A expenses. The key catalyst is the option and license agreement with Sentynl Therapeutics for alvelestat, which includes a non-refundable option fee and potential $40M in upfront and R&D payments upon exercise, plus up to $435M in milestones. Cash runway was extended into late-2027, but the company remains pre-revenue with no approved products and the setrusumab path forward remains uncertain.
Key Financial Metrics
Key Facts
- Net loss for Q2 2026 was $7.0M, compared to $14.6M in Q2 2025.
- Cash and cash equivalents were $30.1M as of June 30, 2026, expected to fund operations into late-2027.
- Entered into an option and license agreement with Sentynl Therapeutics for alvelestat, with potential $40M in upfront and R&D payments on exercise.
- Sentynl has the right to acquire U.S. commercial and global manufacturing rights for alvelestat.
- Mereo and partner Ultragenyx are engaging with regulatory agencies on a potential path forward for setrusumab in OI.
- R&D expenses decreased by $3.6M to $1.8M in Q2 2026 from $5.4M in Q2 2025.
- Revenue was $0 for Q2 2026, compared to $500,000 in Q2 2025.
Financial Impact
Net loss improved by $7.6M year-over-year to $7.0M; cash burn of ~$10.9M in H1 2026; potential $40M upfront from Sentynl option exercise.
Risk Factors
- Setrusumab Phase 3 studies failed primary endpoints; regulatory path forward is uncertain.
- Alvelestat option may not be exercised by Sentynl, removing a key funding source.
- Company is pre-revenue with no approved products; continued operating losses.
- Cash runway guidance excludes potential partnership payments; actual burn may vary.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-343519 |
| Document: mreo-20260811.htm | 0001193125-26-343519 |
| Document: 0001193125-26-343519-index-headers.html | 0001193125-26-343519 |
| Document: 0001193125-26-343519-index.html | 0001193125-26-343519 |
| Document: 0001193125-26-343519.txt | 0001193125-26-343519 |
| 8-K Data (Synthetic) | 0001193125-26-343519 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 19, 2026 9w ago | 8-K | $0.3115 $0.2780 | ▲ +10.75% | ▲ +10.37% | $0.2750 (+11.72%) |
Aug 11, 2026 10w ago | 8-K | $0.3060 $0.3130 | ▲ +2.29% | ▲ +2.69% | $0.2750 (−10.13%) |
Aug 11, 2026 10w ago | Press Release | $0.3060 $0.3130 | ▲ +2.29% | ▲ +2.69% | $0.2750 (−10.13%) |
Aug 11, 2026 10w ago | 8-K | $0.3060 $0.3130 | ▲ +2.29% | ▲ +2.69% | $0.2750 (−10.13%) |
Jun 11, 2026 19w ago | Institutional Cluster | $0.3118 $0.3100 | ▼ −0.58% | ▼ −1.01% | $0.2750 (−11.80%) |
May 12, 2026 23w ago | Press Release | $0.2460 $0.2370 | ▲ +3.66% | ▲ +3.74% | $0.2750 (−11.79%) |
Mar 19, 2026 31w ago | Press Release | $0.3610 $0.3390 | ▼ −6.09% | ▼ −3.88% | $0.2750 (−23.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers